Positron emission tomography (PET) is a non-invasive nuclear imaging technique which uses radioactive tracers. PET scans specifically look at the metabolism of a particular organ or tissue, and uses a tracer dependent on which organ or tissues are the focus of the scan.
PET scans are able to detect biochemical changes in an organ or tissue. These changes can be attributed to the onset of a disease process before any anatomical changes are visible on other imaging processes. Read more.
Single photon emission computed tomography (SPECT) is a form of non-invasive nuclear imaging used in order to determine how organs inside the body work. The scan can be used to illustrate how, for example, the blood flows into the heart and chemical reactions that are happening in the body. Read more.
Different imaging techniques can have different sensitivity in evaluating the response of malignant pleural mesothelioma (MPM) patients to chemotherapy, but a new study found a technique called 18F-FDG-PET/CT to be superior to others, and it called for the method’s inclusion in treatment assessments to help identify those not likely to respond to chemotherapy.
The study, “Metabolic Response Assessment With 18F-FDG-PET/CT Is Superior To Modified RECIST For The Evaluation Of Response To Platinum-Based Doublet Chemotherapy In Malignant Pleural Mesothelioma,” was published in the European Journal of Radiology. Read more.
Preclinical imaging is revolutionizing health-related research, expanding horizons in our knowledge at an unprecedented pace on human physiology, gene expression, physiopathology and disease evolution. Using imaging and transgenic small-animal models, disease progression can be monitored to evaluate candidate therapeutics, molecular tracers, and interventions. Preclinical positron emission tomography (PET) technology in particular is currently experiencing a rapid pace of innovation. Using novel detectors, systems are approaching the theoretical limits of resolution, with Full Field Accuracy and without compromise to sensitivity. Further, PET multimodal integration is evolving. Initial PET systems typically offered PET functional detections only. Later, PET/CT integration provided structural context, typically limited to skeletal anatomy and providing strictly static context. These integrations were relatively technologically direct, with negligible interference between PET and CT. PET/magnetic resonance imaging (MR) integration has been reported, though frequently with compromises in both PET and MR performance. It is only now, with recent advances in PET detector technologies, that truly uncompromised PET/MR integrations can be achieved, offering both sequential and even high field simultaneous data collection. These developments will deliver higher quality data and better physiological context than ever before. This article will highlight an advanced translational research preclinical imaging system for simultaneous PET/MR investigations in mice and rats. Read more.
Clinical manifestations of cardiac sarcoidosis include several heart anomalies, such as left ventricular systolic dysfunction, ventricular arrhythmias, and atrioventricular conduction anomalies, which may lead to heart failure and death. But cardiac sarcoidosis is still difficult to diagnose. Current techniques used to help diagnose the condition include positron emission tomography (PET) scans and computed tomography (CT) scans, or a combination of both, but the results can be inconclusive at times. Read more.